Highlights include:
- Daratumumab + standard care in newly diagnosed MM
- OS with daratumumab + bortezomib/melphalan/prednisone in newly diagnosed MM
- Frontline treatment of elderly non transplant-eligible MM patients using cyclophosphamide, bortezomib, dexamethasone
Download here: Multiple Myeloma Research Review Issue 33